Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance

Journal of Viral Hepatitis

Volumn 22, Issue 11, 2015, Pages 890-896

  Lemoine, Maud ^a,b   Chevaliez, S ^c,d   Bastard, J P ^b,e   Fartoux, L ^a   Chazouilleres O ^a   Capeau, J ^b,e   Pawlotsky, J M ^c,d   Serfaty, L ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e HÔPITAL TENON   (France)

Author keywords

chronic hepatitis C; hepatitis C virus; IL28B; insulin resistance; leptin, adiponectin; tumour necrosis factor alpha

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; CYTOSINE; INSULIN; INTERLEUKIN 28B; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; IL28B GENE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; COMPLICATION; GENETICS; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADIPONECTIN; ADULT; AGED; BIOMARKERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; INTERLEUKINS; LEPTIN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84943819902     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12408     Document Type: Article

References (36)

1. Serfaty L, Capeau J,. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009; 29 (Suppl. 2): 13-25.
2. Negro F,. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010; 59 (9): 1279-1287.
3. Moucari R, Asselah T, Cazals-Hatem D, et al,. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134 (2): 416-423.
4. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL,. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133 (8): 592-599.
5. Deltenre P, Louvet A, Lemoine M, et al,. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011; 55 (6): 1187-1194.
6. Shintani Y, Fujie H, Miyoshi H, et al,. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126 (3): 840-848.
7. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al,. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128 (3): 636-641.
8. Aghemo A, Prati GM, Rumi MG, et al,. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 2012; 56 (5): 1681-1687.
9. Delgado-Borrego A, Jordan SH, Negre B, et al,. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8 (5): 458-462.
10. Simo R, Lecube A, Genesca J, Esteban JI, Hernandez C,. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006; 29 (11): 2462-2466.
11. Kawaguchi T, Ide T, Taniguchi E, et al,. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102 (3): 570-576.
12. Durante-Mangoni E, Zampino R, Marrone A, et al,. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006; 24 (9): 1349-1357.
13. Thompson AJ, Muir AJ, Sulkowski MS, et al,. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 (1): 120-129.e18.
14. Li JH, Lao XQ, Tillmann HL, et al,. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51 (6): 1904-1911.
15. Agundez JA, Garcia-Martin E, Maestro ML, et al,. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS ONE 2012; 7 (5): e37998.
16. Falleti E, Bitetto D, Fabris C, et al,. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 2011; 31 (5): 891-899.
17. Huang JF, Yu ML, Huang CF, et al,. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int 2012; 32 (6): 962-969.
18. Stättermayer AF, Rutter K, Beinhardt S, et al,. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012; 57 (3): 492-498.
19. Petta S, Rosso C, Leung R, et al,. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11 (3): 311-317.e1.
20. Wallace TM, Matthews DR,. The assessment of insulin resistance in man. Diabet Med 2002; 19 (7): 527-534.
21. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24 (2): 289-293.
22. Chevaliez S, Hezode C, Soulier A, et al,. High-dose pegylated interferon-alpha and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology 2011; 141 (1): 119-127.
23. Cua IH, Hui JM, Kench JG, George J,. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48 (3): 723-731.
24. Ogawa E, Furusyo N, Murata M, et al,. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012; 57 (3): 534-540.
25. Degasperi E, Valenti L, Aghemo A, et al,. Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients. Antivir Ther 2014; 19 (8): 747-753.
26. Motta BM, Dongiovanni P, Fargion S, Valenti L,. IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. Dig Liver Dis 2013; 45 (4): 348-349.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (7): 412-419.
28. Romero-Gomez M, Castellano-Megias VM, Grande L, et al,. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003; 98 (5): 1135-1141.
29. Lemoine M, Ratziu V, Kim M, et al,. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009; 29 (9): 1431-1438.
30. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D,. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54 (1): 1-8.
31. Bertoletti A, D'Elios MM, Boni C, et al,. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112 (1): 193-199.
32. Bouvier-Alias M, Patel K, Dahari H, et al,. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36 (1): 211-218.
33. Tillmann HL, Patel K, Muir AJ, et al,. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011; 55 (6): 1195-1200.
34. Abe H, Ochi H, Maekawa T, et al,. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53 (3): 439-443.
35. Petta S, Grimaudo S, Camma C, et al,. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012; 56 (6): 1356-1362.
36. Lawitz E, Ghalib R, Rodriguez-Torres M, et al,. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naïve patients (cosmos study): primary endpoint (SVR12). J Hepatol 2014; 60 (Suppl. 1): S524; 0165.